This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Dermatology, primary care, and pediatric NPs and PAs
Upon completion of this activity, participants should be able to:
Incorporate a co-management approach with shared decision-making into patient and caregiver encounters
Select appropriate therapies for pediatric and adult patients with moderate to severe AD based on patient- and disease-related factors and the efficacy and safety of available therapies
Victoria Garcia-Albea: consultant: Sanofi-Genzyme.
Jonathan Silverberg: consultant: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Sidekick Health; fees for non-CME/CE services: AbbVie, Eli Lilly, Leo, Pfizer, Regeneron, Sanofi; funds for research support (paid to institution): Galderma, Pfizer.
This program has been made available online.